Table 3. Cox regressional univariate and multivariate analysis of CSS in resected PDAC patients.
| Variables | No. of patients (N=1,676) [n (%)] | Univariate analysis | Multivariate analysis | |||
| P | P | HR | 95% CI | |||
| CSS, cancer specific survival; PDAC, pancreatic ductal adenocarcinoma; BMI, body mass index; TBIL, total bilirubin; CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; LN, lymph node; HR, hazard ratio; 95% CI, 95% confidence interval. | ||||||
| Age (year) | 0.007 | 0.102 | 1.13 | 0.98−1.30 | ||
| ≤65 | 1,060 (63.2) | |||||
| >65 | 616 (36.8) | |||||
| BMI (kg/m2) | 0.004 | 0.054 | 0.83 | 0.68−1.00 | ||
| ≤19 | 221 (13.2) | |||||
| >19 | 1,455 (86.8) | |||||
| TBIL (μmol/L) | <0.001 | 0.002 | 1.32 | 1.11−1.56 | ||
| ≤128.29 | 1,300 (77.6) | |||||
| >128.29 | 376 (22.4) | |||||
| CA19-9 (U/mL) | <0.001 | <0.001 | 1.40 | 1.20−1.64 | ||
| ≤500 | 1,244 (74.2) | |||||
| >500 | 432 (25.8) | |||||
| CEA (ng/mL) | <0.001 | 0.032 | 1.18 | 1.01−1.37 | ||
| ≤2.98 | 747 (44.6) | |||||
| >2.98 | 929 (55.4) | |||||
| Site of tumor | 0.009 | 0.169 | 1.13 | 0.95−1.34 | ||
| Body/tail of pancreas | 535 (31.9) | |||||
| Head of pancreas | 1,141 (68.1) | |||||
| Differentiation | <0.001 | <0.001 | 1.64 | 1.44−1.86 | ||
| Well | 74 (4.4) | |||||
| Moderate | 792 (47.3) | |||||
| Poor | 807 (48.2) | |||||
| Undifferentiated | 3 (0.2) | |||||
| T stage | <0.001 | <0.001 | 1.16 | 1.07−1.26 | ||
| T1 | 317 (18.9) | |||||
| T2 | 861 (51.4) | |||||
| T3 | 300 (17.9) | |||||
| T4 | 198 (11.8) | |||||
| N stage | <0.001 | <0.001 | 1.40 | 1.26−1.56 | ||
| N0 | 959 (57.2) | |||||
| N1 | 575 (34.3) | |||||
| N2 | 142 (8.5) | |||||
| Margin | <0.001 | <0.001 | 1.69 | 1.38−2.09 | ||
| R0 | 1,502 (89.6) | |||||
| R1 | 174 (10.4) | |||||
| Adjuvant therapy | <0.001 | <0.001 | 0.64 | 0.56−0.75 | ||
| No | 945 (56.4) | |||||
| Yes | 731 (43.6) | |||||